Source comparison
The Safety Comparison: Ipamorelin vs Other Growth Hormone Secretagogues
Ipamorelin Dose-dependent, peaks 90–120 min None detected at doses up to 2.0 mcg/kg None detected Mild injection site reactions (3–5% incidence) Cleanest safety profile. Selective GH release with minimal off-target effects GHRP-6 Strong, rapid onset Moderate e
This comparison does not assign a generated winner or score.
- Ipamorelin
- Dose-dependent, peaks 90–120 min
- None detected at doses up to 2.0 mcg/kg
- None detected
- Mild injection site reactions (3–5% incidence)
- Cleanest safety profile. Selective GH release with minimal off-target effects
- GHRP-6
- Strong, rapid onset
- Moderate elevation (15–30% increase from baseline)
- Moderate elevation
- Increased hunger, water retention, tingling/numbness in extremities
- Effective but cortisol and hunger side effects limit tolerability
- GHRP-2
- Strong, dose-dependent
- Mild to moderate elevation (10–20% increase)
- Mild elevation
- Flushing, headache, increased appetite
- Better than GHRP-6 but still triggers some cortisol response
- Hexarelin
- Very strong, highest GH amplitude
- Significant elevation, especially with chronic use
- Significant elevation
- Nausea, desensitization with prolonged use, prolactin-related effects
- Potent but rapid receptor desensitization and cortisol issues
- CJC-1295 (DAC)
- Sustained elevation over 6–8 days
- Injection site nodules, rare vasodilation
- Long half-life creates sustained exposure. Different risk profile
- The comparison reveals why ipamorelin is considered the safest option for researchers prioritizing tolerability. GHRP-6 and GHRP-2 both elevate cortisol to some degree, which becomes problematic with repeated dosing. Chronic cortisol exposure suppresses immune function, impairs recovery, and can interfere with sleep quality. Hexarelin's desensitization issue means that after 2–4 weeks of daily use, GH response diminishes significantly, requiring cycling protocols that complicate study design. Ipamorelin shows no evidence of receptor desensitization even with daily administration for 15+ days, based on the 2012 elderly cohort study.